Zuranolone

🧮 Dose calculator

Postpartum depression · Regimen source: FDA Zurzuvae · 2.1

• • If CNS depressant effects: 40 mg. Severe hepatic impairment (Child-Pugh C) or eGFR <60: 30 mg. Not studied beyond 14 days. FDA Zurzuvae · 2.1FDA Zurzuvae · 2.3FDA Zurzuvae · 2.4

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyDangerous / avoid

  Label: can cause fetal harm. Dangerous in pregnancy. FDA Zurzuvae · 8.1

  “… ntalhealth.org/research/pregnancyregistry/antidepressants/ Risk Summary Based on findings from animal studies, ZURZUVAE may cause fetal harm.”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Zurzuvae · 8.2

  “Risk Summary Available data from a clinical lactation study in 14 women indicate that zuranolone is present in low levels in human milk (see Data ).”

• 👶 ChildrenSafety not established

  Label: safety and effectiveness in children have not been established. FDA Zurzuvae · 8.4

  “The safety and effectiveness of ZURZUVAE in pediatric patients have not been established.”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Zurzuvae · 8.5

  “PPD is a condition associated with pregnancy; there is no geriatric experience with ZURZUVAE in patients with PPD.”

• ⚥ Females & males of reproductive potentialUse with caution

  Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Zurzuvae · 8.3

  “Contraception Advise female patients of reproductive potential to use effective contraception during treatment with ZURZUVAE and for 1 week after the final dose.”